Linked Life Data

20964660

Source:http://linkedlifedata.com/resource/pubmed/id/20964660

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20964660rdf:typepubmed:Citationlld:pubmed
pubmed-article:20964660lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0085756lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0005680lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0086409lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0086528lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0036270lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0033860lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0053523lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0065767lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:20964660lifeskim:mentionsumls-concept:C0524527lld:lifeskim
pubmed-article:20964660pubmed:issue11lld:pubmed
pubmed-article:20964660pubmed:dateCreated2010-10-22lld:pubmed
pubmed-article:20964660pubmed:abstractTextThe calcipotriene/betamethasone dipropionate two-compound scalp formulation has been shown to be safe and effective in the treatment of scalp psoriasis over 8 weeks, but the patients studied were mainly White and non-Hispanic. The aim of this study was to evaluate the efficacy and safety of the two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients. A total of 99 Hispanic/Latino and 78 Black/African American patients were randomized double-blind in a 3:1 ratio to 8 weeks of once daily treatment of scalp psoriasis with either the two-compound scalp formulation (n=135) or its vehicle (n=42). In the two-compound group, 71.9% of patients had cleared or minimal disease at week 8 by the investigator's global assessment compared to 40.5% in the vehicle group (odds ratio 3.30; 95% CI 1.62-6.72; P<0.001). For the five secondary efficacy response criteria, three (total sign score, thickness of scalp psoriasis, patient's global assessment) showed that two-compound scalp formulation was statistically significantly more effective than its vehicle, and the other two (redness and scaliness of scalp psoriasis) approached statistical significance in favor of the two-compound scalp formulation. There was no statistically significant difference (P=1.00) between the percentage of patients with adverse reactions in the two-compound group (7.0%) and the vehicle group (7.9%). The two-compound scalp formulation is safe and effective in the treatment of scalp psoriasis over 8 weeks in Hispanic/Latino and Black/African American patients.lld:pubmed
pubmed-article:20964660pubmed:languageenglld:pubmed
pubmed-article:20964660pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20964660pubmed:citationSubsetIMlld:pubmed
pubmed-article:20964660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20964660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20964660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20964660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20964660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20964660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20964660pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20964660pubmed:statusMEDLINElld:pubmed
pubmed-article:20964660pubmed:monthNovlld:pubmed
pubmed-article:20964660pubmed:issn1365-4632lld:pubmed
pubmed-article:20964660pubmed:authorpubmed-author:TyringStephen...lld:pubmed
pubmed-article:20964660pubmed:authorpubmed-author:FosterRichard...lld:pubmed
pubmed-article:20964660pubmed:authorpubmed-author:LeeMarkMlld:pubmed
pubmed-article:20964660pubmed:authorpubmed-author:HamiltonTiffa...lld:pubmed
pubmed-article:20964660pubmed:authorpubmed-author:MendozaNatali...lld:pubmed
pubmed-article:20964660pubmed:authorpubmed-author:BibbyAdrianAlld:pubmed
pubmed-article:20964660pubmed:authorpubmed-author:AppellMelanie...lld:pubmed
pubmed-article:20964660pubmed:copyrightInfo© 2010 The International Society of Dermatology.lld:pubmed
pubmed-article:20964660pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20964660pubmed:volume49lld:pubmed
pubmed-article:20964660pubmed:ownerNLMlld:pubmed
pubmed-article:20964660pubmed:authorsCompleteYlld:pubmed
pubmed-article:20964660pubmed:pagination1328-33lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:meshHeadingpubmed-meshheading:20964660...lld:pubmed
pubmed-article:20964660pubmed:year2010lld:pubmed
pubmed-article:20964660pubmed:articleTitleA calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial.lld:pubmed
pubmed-article:20964660pubmed:affiliationCenter for Clinical Studies, Department of Dermatology, University of Texas Health Science Center, Houston, TX, USA.lld:pubmed
pubmed-article:20964660pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20964660pubmed:publicationTypeRandomized Controlled Triallld:pubmed